Aprepitant-13C2,d2 (Major) |
|
| Synonyms: 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one-13C2,d2; Emend-13C2,d2; MK-0869-13C2,d2; | |
| Cat. No.: A66262 | CAS No.: Unlabelled: 170729-80-4 |
| MDL.: | Formula: C2113C2H19D2F7N4O3 |
| F.W.538.42 | Purity: 99％ |
| Storage: -20°C Freezer | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 1mg | POA | Enter qty and click checkbox |
| Catalog Number： | A66262 | CAS No.: | Unlabelled: 170729-80-4 | |
| MDL: | Formula: | C2113C2H19D2F7N4O3 | ||
| F.W.: | 538.42 | Purity: | 99％ | |
| Package: | Unit: | mg | ||
| Appearance: | Off-White Solid | M.P.: | 244-246°C | |
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | Stability: | Chloroform, Methanol | ||
| Storage: | -20°C Freezer | Category: | Reference Standard | |
| Reference: | Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998), Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001), Van Belle, S., et al.: Cancer, 94, 3032 (2002), Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006), | |||
| Application: | This product is deuterated at the 1 position and on the ajacent methyl. The 1 position is the benylic position of the bis(trifluoromethyl) phenyl. This compound has a mixture of 1 to 4 deuterium atoms, there is no detectable unlabeled material. Aprepitant is a structurally novel substance P neurokinin 1 (NK1) receptor antagonist. In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. | |||
| Category: | Chiral Reagents, Heterocycles, Isotope Labelled Compounds, Pharmaceuticals, Intermediates & Fine Chemicals, | |||